HK1026429A1 - New formulation - Google Patents

New formulation

Info

Publication number
HK1026429A1
HK1026429A1 HK00105603A HK00105603A HK1026429A1 HK 1026429 A1 HK1026429 A1 HK 1026429A1 HK 00105603 A HK00105603 A HK 00105603A HK 00105603 A HK00105603 A HK 00105603A HK 1026429 A1 HK1026429 A1 HK 1026429A1
Authority
HK
Hong Kong
Prior art keywords
new formulation
formulation
new
Prior art date
Application number
HK00105603A
Other languages
English (en)
Inventor
Joanne Broadhead
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20407718&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1026429(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Publication of HK1026429A1 publication Critical patent/HK1026429A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK00105603A 1997-07-11 2000-09-05 New formulation HK1026429A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9702680A SE9702680D0 (sv) 1997-07-11 1997-07-11 New formulation
PCT/SE1998/001287 WO1999002542A1 (en) 1997-07-11 1998-06-29 New formulation

Publications (1)

Publication Number Publication Date
HK1026429A1 true HK1026429A1 (en) 2000-12-15

Family

ID=20407718

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00105603A HK1026429A1 (en) 1997-07-11 2000-09-05 New formulation

Country Status (36)

Country Link
US (1) US6130208A (is)
EP (1) EP1000079B1 (is)
JP (1) JP4950380B2 (is)
KR (1) KR100786654B1 (is)
CN (2) CN1864696A (is)
AR (1) AR013157A1 (is)
AT (1) ATE340801T1 (is)
AU (1) AU8362598A (is)
BR (1) BR9810703A (is)
CA (1) CA2295628C (is)
CY (1) CY1105805T1 (is)
CZ (1) CZ298110B6 (is)
DE (1) DE69836023T2 (is)
DK (1) DK1000079T3 (is)
EE (1) EE04119B1 (is)
ES (1) ES2273425T3 (is)
HK (1) HK1026429A1 (is)
HU (1) HU226489B1 (is)
ID (1) ID24716A (is)
IL (2) IL133868A0 (is)
IS (1) IS2439B (is)
MY (1) MY116421A (is)
NO (1) NO329918B1 (is)
NZ (1) NZ502073A (is)
PL (1) PL192768B1 (is)
PT (1) PT1000079E (is)
RU (1) RU2216330C2 (is)
SA (1) SA98190328B1 (is)
SE (1) SE9702680D0 (is)
SI (1) SI1000079T1 (is)
SK (1) SK285766B6 (is)
TR (1) TR200000006T2 (is)
TW (1) TW585764B (is)
UA (1) UA65576C2 (is)
WO (1) WO1999002542A1 (is)
ZA (1) ZA985669B (is)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879567B2 (en) * 2004-10-05 2011-02-01 Asahi Kasei Pharma Corporation Method for stabilizing coenzyme and composition therefor
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20120141468A1 (en) * 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
JP5597202B2 (ja) 2009-08-28 2014-10-01 第一三共株式会社 ３−（ビアリールオキシ）プロピオン酸誘導体
PT2498731T (pt) 2009-11-11 2020-02-21 Chiesi Farm Spa Métodos de tratamento ou prevenção de uma trombose de endoprótese
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
RU2606845C2 (ru) * 2010-12-10 2017-01-10 СИГМАФАРМ ЛЭБОРЭТОРИЗ, ЭлЭлСи Высокостабильные композиции перорально активных аналогов нуклеотидов или перорально активных пролекарств аналогов нуклеотидов
CN103582480B (zh) 2011-02-09 2016-03-16 医药公司 治疗肺高压的方法
ES2657019T3 (es) 2011-08-17 2018-03-01 Samuel Shiber Catéter giratorio adaptativo para abrir vasos corporales obstruidos
PL2964233T3 (pl) 2013-03-09 2022-04-25 Chiesi Farmaceutici S.P.A. Sposoby leczenia, zmniejszania częstości występowania i(lub) profilaktyki zdarzeń niedokrwiennych
CN103772461A (zh) * 2014-01-06 2014-05-07 南京正科制药有限公司 一种坎格雷洛晶型ⅰ
WO2016114818A1 (en) 2015-01-14 2016-07-21 The Medicines Company Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
KR20200018481A (ko) 2017-06-23 2020-02-19 키에시 파르마슈티시 엣스. 피. 에이. 체폐동맥 션트 혈전증의 예방 방법
TW202016088A (zh) 2018-06-19 2020-05-01 德商Ｕｃｂ製藥有限公司 吡啶基及吡基-（氮）吲哚磺醯胺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5637967B2 (is) * 1973-05-17 1981-09-03
JPS5874966A (ja) * 1981-10-28 1983-05-06 Mikuni Jukogyo Kk 高圧往復動機の軸封装置
JPS5874696A (ja) * 1981-10-30 1983-05-06 株式会社　ヤトロン アデノシン三リン酸の安定化方法
AU659645B2 (en) * 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
KR0131678B1 (ko) * 1991-12-09 1998-04-17 유미꾸라 레이이찌 파라티로이드 호르몬류의 안정화 조성물
PL175623B1 (pl) * 1993-02-10 1999-01-29 Astra Pharma Prod N-alkilo-2-podstawione analogi ATP, sposób ich wytwarzania i kompozycja farmaceutyczna je zawierająca
ZA949715B (en) * 1993-12-14 1996-06-06 Lilly Co Eli Aqueous solution inclusion complexes of benzothiophene compounds with water soluble cyclodextrins and pharmaceutical formulations and methods thereof
DE4405426A1 (de) * 1994-02-21 1995-08-24 Boehringer Mannheim Gmbh Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate
CA2223921A1 (en) * 1995-06-07 1996-12-19 Francis C. Szoka, Jr. Stabilization of polynucleotide complexes
FR2740686B1 (fr) * 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
ID21635A (id) * 1996-12-20 1999-07-08 Astra Pharma Prod Komposisi farmasi untuk pengeringan beku

Also Published As

Publication number Publication date
NO20000123L (no) 2000-03-03
ES2273425T3 (es) 2007-05-01
SK183699A3 (en) 2000-07-11
HUP0002622A2 (hu) 2001-05-28
CN1864696A (zh) 2006-11-22
DE69836023D1 (de) 2006-11-09
WO1999002542A1 (en) 1999-01-21
PL192768B1 (pl) 2006-12-29
SK285766B6 (sk) 2007-07-06
TW585764B (en) 2004-05-01
JP2001509512A (ja) 2001-07-24
DK1000079T3 (da) 2006-11-20
AU8362598A (en) 1999-02-08
NO329918B1 (no) 2011-01-24
CA2295628C (en) 2008-07-29
IL133868A0 (en) 2001-04-30
SA98190328B1 (ar) 2006-08-15
CA2295628A1 (en) 1999-01-21
ID24716A (id) 2000-08-03
NZ502073A (en) 2001-09-28
RU2216330C2 (ru) 2003-11-20
CZ298110B6 (cs) 2007-06-27
SI1000079T1 (sl) 2007-08-31
IL133868A (en) 2010-05-17
IS2439B (is) 2008-11-15
HUP0002622A3 (en) 2002-04-29
KR20010021647A (ko) 2001-03-15
US6130208A (en) 2000-10-10
EP1000079A1 (en) 2000-05-17
DE69836023T2 (de) 2007-04-12
PT1000079E (pt) 2006-12-29
TR200000006T2 (tr) 2000-07-21
IS5331A (is) 1999-12-30
SE9702680D0 (sv) 1997-07-11
EE200000022A (et) 2000-10-16
ATE340801T1 (de) 2006-10-15
PL337970A1 (en) 2000-09-11
AR013157A1 (es) 2000-12-13
ZA985669B (en) 1999-01-11
UA65576C2 (uk) 2004-04-15
EE04119B1 (et) 2003-08-15
CN1263533A (zh) 2000-08-16
HU226489B1 (en) 2009-03-02
EP1000079B1 (en) 2006-09-27
JP4950380B2 (ja) 2012-06-13
CY1105805T1 (el) 2011-02-02
CZ200083A3 (cs) 2000-06-14
MY116421A (en) 2004-01-31
NO20000123D0 (no) 2000-01-10
BR9810703A (pt) 2000-08-08
KR100786654B1 (ko) 2007-12-21

Similar Documents

Publication Publication Date Title
IL135295A0 (en) 2-methyl-thieno-benzodiazepine formulation
GB9715751D0 (en) Formulations
ZA9811461B (en) New formulation
GB9726916D0 (en) Nasal formulation
DE69837702D1 (en) Lastsensor
ZA9710601B (en) Novel formulation
GB2323024B (en) Mopheads
ZA985669B (en) New formulation
IL132989A0 (en) Carotenoid formulation
GB9724544D0 (en) Novel Formulation
ZA9810184B (en) New phenyl-alkyl-imidazoles
GB9727518D0 (en) Use
EP0968655A4 (en) SPREAD
GB9725061D0 (en) Revitalisation formulation
GB9810180D0 (en) Novel formulation
GB9706957D0 (en) Formulation
GB9615628D0 (en) Formulation
GB9725275D0 (en) Formulation
GB9721807D0 (en) Formulation
GB9704521D0 (en) Formulations
GB9703099D0 (en) Formulations
GB9703100D0 (en) Formulations
GB9703101D0 (en) Formulations
GB9823645D0 (en) Formulation
SI1119359T1 (en) 2-methyl-thieno-benzodiazepine formulation

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20180628